Response to the NICE recommendations

The National Institute for Health and Care Excellence (NICE) published their guidance to clinicians on the 11th of November 2019 regarding the prescribing of Cannabis-Based Medicinal Products (CBMPs). Drug Science welcomes this news from NICE as it shows the start of a more rational approach to medical cannabis. However, it must be emphasised that this  …


Project Twenty21

Drug Science launched Europe’s first and biggest national medical cannabis registry, called Project Twenty21, on the 7th November 2019. Project TWENTY21 will enrol 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis – with an aim to demonstrate to policymakers that medical cannabis  …


Medical Cannabis Student Educational Slides

On the 1st of November 2018, medicinal cannabis products were removed from schedule 1 and placed in schedule 2 of the Misuse of Drugs Regulations 2001. This change in the law has left patients, medical professionals and law enforcement perplexed about who should and who should not have access to medicinal cannabis. As access to  …


Medical Cannabis Education

Drug Science is asked frequently about medical cannabis – what it is, what it can be used for, who can prescribe it and how to regulate it.  We’ve developed different ways to help doctors, patients and professionals understand this complex, emerging field, and our education programmes are central to this MEDIC (Medical Education in Cannabinoids)  …


NICE on cannabidiol for childhood epilepsy

At the end of last week, NICE released their initial appraisal on cannabidiol in the form of Epidiolex for childhood epilepsy.  As predicted by Drug Science experts they found against it on the grounds of cost-benefit. We don’t have the company submission regarding cost/benefit analysis, and consequently cannot comment on those, but we can reflect  …